Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
Deregulation of PRDM5 promotes cell proliferation by regulating JAK/STAT signaling pathway through SOCS1 in human lung adenocarcinoma.
Item request has been placed!
×
Item request cannot be made.
×
![loading](/sites/all/modules/hf_eds/images/loading.gif)
Processing Request
- معلومة اضافية
- المصدر:
Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
- بيانات النشر:
Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
- الموضوع:
- نبذة مختصرة :
Background: PRDM5 is considered a tumor suppressor in several types of solid tumors and is involved in multiple cellular processes. However, target genes regulated by PRDM5 in lung cancer and its potential mechanism are poorly defined.
Methods: Survival analysis was conducted using Kaplan-Meier estimates based on the online databases. RNA-sequencing and bioinformatics analysis were performed to identify the differentially expressed genes in PRDM5-overexpressed A549 cells.
Results: We observed deregulated PRDM5 in several lung adenocarcinoma cell lines and its association with a poor prognosis. PRDM5 overexpression inhibited the proliferation of lung adenocarcinoma cells in vitro and suppressed tumor growth in a xenograft model. PRDM5 upregulated the promoter activity of SOCS1, which then inhibited the phosphorylation of JAK2 and STAT3.
Conclusions: Our study suggests that the low expression of PRDM5 promotes the proliferation of lung adenocarcinoma cells by downregulating SOCS1 and then upregulating the JAK2/STAT3 signaling pathway.
(© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- References:
Trends Pharmacol Sci. 2019 May;40(5):298-308. (PMID: 30948191)
Bioessays. 2012 Jan;34(1):50-60. (PMID: 22028065)
Int J Neurosci. 2021 Feb;131(2):144-153. (PMID: 32083978)
PLoS One. 2011;6(11):e27346. (PMID: 22087297)
Nat Commun. 2020 Oct 21;11(1):5341. (PMID: 33087723)
Science. 2017 Mar 17;355(6330):1158-1163. (PMID: 28302824)
Mol Med Rep. 2017 Nov;16(5):6405-6411. (PMID: 28901399)
Mol Cell Biol. 2007 Oct;27(19):6889-902. (PMID: 17636019)
Nature. 2018 Jan 24;553(7689):446-454. (PMID: 29364287)
Int J Cancer. 2019 Jan 1;144(1):80-88. (PMID: 29978464)
Br J Cancer. 2015 Jul 28;113(3):365-71. (PMID: 26151455)
Cytokine. 2019 Sep;121:154733. (PMID: 31154249)
J Cancer. 2021 Oct 3;12(22):6921-6930. (PMID: 34659579)
Nat Rev Cancer. 2017 Aug;17(8):502-508. (PMID: 28643779)
BMC Evol Biol. 2007 Oct 04;7:187. (PMID: 17916234)
Mol Cell Biol. 2013 Nov;33(22):4504-16. (PMID: 24043305)
Oncogene. 2004 Jun 17;23(28):4903-10. (PMID: 15077163)
BMC Cancer. 2017 Feb 24;17(1):157. (PMID: 28235401)
Int J Cancer. 2012 Sep 15;131(6):1287-96. (PMID: 22095154)
BMC Cancer. 2010 Apr 30;10:178. (PMID: 20433750)
Int J Clin Exp Pathol. 2014 Apr 15;7(5):2305-11. (PMID: 24966940)
Nat Commun. 2018 Apr 19;9(1):1558. (PMID: 29674694)
Otol Neurotol. 2021 Jan;42(1):e94-e100. (PMID: 33201080)
CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
Onco Targets Ther. 2018 May 22;11:2991-3002. (PMID: 29872311)
Clin Exp Pharmacol Physiol. 2022 Mar;49(3):370-379. (PMID: 34757658)
Cancer Med. 2023 Feb;12(4):4568-4578. (PMID: 36127737)
Genome Res. 2020 Sep;30(9):1217-1227. (PMID: 32820006)
- Contributed Indexing:
Keywords: JAK/STAT signaling pathway; PRDM5; SOCS1; lung adenocarcinoma
- الرقم المعرف:
0 (Suppressor of Cytokine Signaling Proteins)
0 (STAT3 Transcription Factor)
0 (SOCS1 protein, human)
0 (Suppressor of Cytokine Signaling 1 Protein)
0 (PRDM5 protein, human)
0 (DNA-Binding Proteins)
0 (Transcription Factors)
- الموضوع:
Date Created: 20220920 Date Completed: 20230302 Latest Revision: 20230317
- الموضوع:
20230320
- الرقم المعرف:
PMC9972168
- الرقم المعرف:
10.1002/cam4.5251
- الرقم المعرف:
36127737
No Comments.